Antibody Therapy Market (By Type: Monoclonal Antibodies, Antibody Drug Conjugates; By End User: Hospitals, Specialty Centers, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antibody Therapy Market 

5.1. COVID-19 Landscape: Antibody Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antibody Therapy Market, By Type

8.1. Antibody Therapy Market, by Type, 2024-2033

8.1.1. Monoclonal Antibodies

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Antibody Drug Conjugates

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Antibody Therapy Market, By End User

9.1. Antibody Therapy Market, by End User, 2024-2033

9.1.1. Hospitals

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Specialty Centers

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Others

9.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Antibody Therapy Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Type (2021-2033)

10.1.2. Market Revenue and Forecast, by End User (2021-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.1.3.2. Market Revenue and Forecast, by End User (2021-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.1.4.2. Market Revenue and Forecast, by End User (2021-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Type (2021-2033)

10.2.2. Market Revenue and Forecast, by End User (2021-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.2.3.2. Market Revenue and Forecast, by End User (2021-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.2.4.2. Market Revenue and Forecast, by End User (2021-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Type (2021-2033)

10.2.5.2. Market Revenue and Forecast, by End User (2021-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Type (2021-2033)

10.2.6.2. Market Revenue and Forecast, by End User (2021-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.3.2. Market Revenue and Forecast, by End User (2021-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.3.3.2. Market Revenue and Forecast, by End User (2021-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.3.4.2. Market Revenue and Forecast, by End User (2021-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Type (2021-2033)

10.3.5.2. Market Revenue and Forecast, by End User (2021-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Type (2021-2033)

10.3.6.2. Market Revenue and Forecast, by End User (2021-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.4.2. Market Revenue and Forecast, by End User (2021-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.4.3.2. Market Revenue and Forecast, by End User (2021-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.4.4.2. Market Revenue and Forecast, by End User (2021-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Type (2021-2033)

10.4.5.2. Market Revenue and Forecast, by End User (2021-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Type (2021-2033)

10.4.6.2. Market Revenue and Forecast, by End User (2021-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Type (2021-2033)

10.5.2. Market Revenue and Forecast, by End User (2021-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.5.3.2. Market Revenue and Forecast, by End User (2021-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.5.4.2. Market Revenue and Forecast, by End User (2021-2033)

Chapter 11. Company Profiles

11.1. Bristol-Myers Squibb

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. GlaxoSmithKline plc

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Takeda Pharmaceuticals

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Eli Lilly and Company

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Merck & Co, Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Seagen, Johnson & Johnson

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Novartis AG

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Regeneron Pharmaceuticals

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. F. Hoffmann-La Roche Ltd.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Merck & Co, IncSeagen

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample